The TEAL study showed that employing a combination of T-DM1, lapatinib, and nab-paclitaxel for the neoadjuvant treatment of patients with HER2-positive breast cancer yielded improved responses compared to the standard paclitaxel, trastuzumab, and pertuzumab combination, which was accentuated in the traditionally challenging hormone receptor-positive subset [21]. Here, ERBB2 is linked to breast carcinoma.